^
Association details:
| Biomarker: | ALK rearrangement + ALK T1151M + ALK L1198F + EGFR A839V |
|---|---|
| Cancer: | Non Small Cell Lung Cancer |
| Drug: | Xalkori (crizotinib) (ALK inhibitor) |
| Direction: | Resistant |
Evidence:
Source:
Title:
Acquired Resistance Mutations to ALK Inhibitors Identified by Single Circulating Tumor Cell Sequencing in ALK-Rearranged Non-Small-Cell Lung Cancer
Published date:
08/22/2019
Excerpt:
We asked whether single circulating tumor cell (CTC) sequencing can inform on resistance mutations to ALK inhibitors and underlying tumor heterogeneity in ALK-rearranged NSCLC....We investigated the VAF of resistance mutations in CTCs from 14 ALK-rearranged patients progressing on crizotinib...P12 harbored the ALKT1151M and ALKL1198F mutations in different CTC specimens (VAFs, 14% and 6% respectively). In addition, this patient harbored a total of 16 “off-target” mutations (VAF ranging from 3% to 99%) in different CTC specimens including an EGFRA839V mutation (VAF, 99%).
DOI:
10.1158/1078-0432.CCR-19-1176
